Identify R&D opportunities through pipeline benchmarking, clinical-stage analysis, unmet needs, collaborations, licensing, mergers and acquisitions.Dublin, Oct. 21, 2026 (GLOBE NEWSWIRE) -- "Atopic ...

TRIV-573, potential first-in-class KLK5/7 x IL-13 bispecific, simultaneously targets skin barrier dysfunction and inflammation to address ...

NBC Selected independently determines what we cover and recommend. When you click on or buy through our links, we earn a commission. Learn more. Bianca Alvarez Former Associate Reporter Since I was ...

Lauren O’Connor, MS, RDN, is a health and lifestyle writer and five-time cookbook author based in Los Angeles. She is a registered dietitian with over 15 years of experience in the field, specializing ...

Everyday Health independently vets all recommended products. If you purchase a featured product, we may be compensated. Learn why you can trust us. Everyday Health independently vets all recommended ...

The marked differences of how a JAK inhibitor and an anti-IL-4 inhibitor affect proteomics in the treatment of AD provide new ...

Everyday Health independently vets all recommended products. If you purchase a featured product, we may be compensated. Learn why you can trust us. Everyday Health independently vets all recommended ...

Early-life factors, including family allergy history and moisturiser use, may help predict eczema risk in infants, according ...

For decades, the relationship between food allergies and eczema/atopic dermatitis (AD) has been one of the most contentious ...

The cities with the best quality of life have high scores on U.S. News’ Quality of Life Index. It measures how satisfied residents are with their daily lives, and takes into account factors like crime ...

NIGERIA DEVELOPMENT UPDATE (NDU) - October 2026 Edition: Nigeria’s growth has remained resilient, while higher oil prices have bolstered fiscal revenues and external balances, despite temporarily ...

Additionally, long-term durable outcomes with Olumiant (baricitinib) in pediatric patients 12 years of age and older with severe alopecia areata will be presented from the BRAVE-AA-PEDS clinical trial ...